North America Arthritic Therapeutic Market Size, Share & Trends Analysis Report By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others), By Product Type, By Country and Growth Forecast, 2023 - 2030

North America Arthritic Therapeutic Market Size, Share & Trends Analysis Report By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others), By Product Type, By Country and Growth Forecast, 2023 - 2030


The North America Arthritic Therapeutic Market would witness market growth of 4.5% CAGR during the forecast period (2023-2030).

The US market dominated the North America Arthritic Therapeutic Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $31,321.7 Million by 2030. The Canada market is experiencing a CAGR of 6.8% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.9% during (2023 - 2030).

Adopting arthritic therapeutics hinges on the availability of safe and efficacious treatments that effectively alleviate symptoms, preserve joint function, and enhance overall quality of life. Clinical trials and real-world evidence demonstrating the benefits of various pharmacological and non-pharmacological interventions are crucial in informing treatment decisions and shaping clinical practice guidelines.

The adoption of this is influenced by the availability and accessibility of healthcare infrastructure, like rheumatology clinics, primary care providers, physical therapy facilities, and diagnostic services. Adequate healthcare resources, including trained personnel, medical equipment, and pharmaceutical supplies, are essential for delivering comprehensive arthritis care and implementing evidence-based treatment protocols.

According to the Canadian Institute for Health Information, Canada’s senior population of those 65 and older will expand by 68% over the next 20 years. It has more than tripled in size in the last 40 years. In 2017, it was around 6.2 million. It is anticipated to reach 10.4 million in 2037. This population in Canada is projected to increase by 2.1 times by 2037 from its size in 2017. Arthritis is one of the most common chronic conditions among older adults in Canada. Hence, the factors mentioned above will drive the regional market growth.

Based on Application, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others. Based on Product Type, the market is segmented into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease Modified Anti-rheumatoid Drugs (DMARDs), Biologics, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled
  • AbbVie, Inc.
  • Pfizer, Inc.
  • Amgen, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Viatris, Inc.
  • Bausch Health Companies, Inc.
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
North America Arthritic Therapeutic Market Report Segmentation

By Application
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Osteoarthritis
  • Ankylosing Spondylitis
  • Others
By Product Type
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Disease Modified Anti-rheumatoid Drugs (DMARDs)
  • Biologics
  • Others
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Arthritic Therapeutic Market, by Application
1.4.2 North America Arthritic Therapeutic Market, by Product Type
1.4.3 North America Arthritic Therapeutic Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. Recent Strategies Deployed in the Arthritic Therapeutic Market
Chapter 5. North America Arthritic Therapeutic Market, by Application
5.1 North America Rheumatoid Arthritis Market, by Country
5.2 North America Psoriatic Arthritis Market, by Country
5.3 North America Osteoarthritis Market, by Country
5.4 North America Ankylosing Spondylitis Market, by Country
5.5 North America Others Market, by Country
Chapter 6. North America Arthritic Therapeutic Market, by Product Type
6.1 North America Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Country
6.2 North America Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Country
6.3 North America Biologics Market, by Country
6.4 North America Others Market, by Country
Chapter 7. North America Arthritic Therapeutic Market, by Country
7.1 US Arthritic Therapeutic Market
7.1.1 US Arthritic Therapeutic Market, by Application
7.1.2 US Arthritic Therapeutic Market, by Product Type
7.2 Canada Arthritic Therapeutic Market
7.2.1 Canada Arthritic Therapeutic Market, by Application
7.2.2 Canada Arthritic Therapeutic Market, by Product Type
7.3 Mexico Arthritic Therapeutic Market
7.3.1 Mexico Arthritic Therapeutic Market, by Application
7.3.2 Mexico Arthritic Therapeutic Market, by Product Type
7.4 Rest of North America Arthritic Therapeutic Market
7.4.1 Rest of North America Arthritic Therapeutic Market, by Application
7.4.2 Rest of North America Arthritic Therapeutic Market, by Product Type
Chapter 8. Company Profiles
8.1 AbbVie, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.2.6 SWOT Analysis
8.3 Amgen, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.3.6 SWOT Analysis
8.4 Novartis AG
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.4.6 SWOT Analysis
8.5 F. Hoffmann-La Roche Ltd.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Viatris, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Trials and Approvals:
8.6.6 SWOT Analysis
8.7 Bausch Health Companies, Inc
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Sanofi S.A.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.6 SWOT Analysis
8.9 Merck & Co., Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.6 SWOT Analysis
8.10. Bristol-Myers Squibb Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings